Mirvetuximab Soravtansine Positioned as New Standard in Frα+ Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine-gynx demonstrated a 35% reduction in the risk of disease progression or death compared with investigator’s choice of chemotherapy in patients with folate receptor alpha-high, platinum-resistant ovarian cancer.
Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy
Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.
BI 764532 Shows Early Efficacy, Manageable Tolerability in DLL3+ SCLC and Neuroendocrine Carcinoma
When administered at doses of 90 μg/kg or higher, the novel DLL3-targeting T-cell engager, BI 764532, was found to have an acceptable toxicity profile and to elicit encouraging responses in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.
Talquetamab Plus Daratumumab Produces Potent Responses in R/R Multiple Myeloma
June 4th 2023Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.
Dostarlimab Plus Chemo Leads to PFS Improvement in dMMR/MSI-H Advanced Endometrial Cancer
June 4th 2023The combination of dostarlimab with standard-of-care carboplatin and paclitaxel elicited a statistically significant and clinically meaningful improvement in progression-free survival vs carboplatin/paclitaxel plus placebo in patients with mismatch repair–deficient/microsatellite instability–high advanced or recurrent endometrial cancer.
Dr Roddie on Obe-cel in R/R B-ALL
June 3rd 2023Claire Roddie, MD, discusses the patient population and topline efficacy findings from the phase 1/2 FELIX trial, which is investigating the CD19-directed CAR T-cell therapy obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Teclistamab/Talquetamab Combo Shows Early Safety, Efficacy in R/R Multiple Myeloma
Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.
Efficacy of CLDN6-Directed CAR T Therapy Is Maintained With Automated Manufacturing in Solid Tumors
June 3rd 2023When manufactured via automated process the CLDN6-directed CAR T-cell therapy, BNT211, demonstrated encouraging signs of activity and a manageable safety profile with or without the addition of CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI
June 3rd 2023Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.
Real-World Data Detail Potential Benefits of Darolutamide Over Other ARIs in nmCRPC
June 3rd 2023Patients with nonmetastatic castration-resistant prostate cancer who received darolutamide were observed to have a longer time to treatment discontinuation and progression to metastatic castration-resistant disease than those who received enzalutamide or apalutamide.
Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC
The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.
NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC
June 3rd 2023Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma.
The addition of durvalumab to standard upfront therapy with chemotherapy and bevacizumab followed by maintenance bevacizumab, durvalumab, and olaparib led to a statistically significant improvement in progression-free survival compared with chemotherapy and bevacizumab alone in patients with newly diagnosed, advanced ovarian cancer without a BRCA1/2 mutation.
Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL
Brexucabtagene autoleucel elicited high rates of complete remission with minimal residual disease negativity in real-world patients with relapsed or refractory B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment, according to data from a retrospective study.
Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL
Obecabtagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS
Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.
Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer
Simple hysterectomy was found to be noninferior to radical hysterectomy and pelvic node dissection in patients with low-risk, early-stage cervical cancer, according to results of the Canadian Cancer Trials Group CX.5/SHAPE trial.